NEJM February 19 2026 Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

This Week In Medicine · Feb 19, 2026 · 19m

This clinical study evaluates the effectiveness of combining two targeted immunotherapies, teclistamab and daratumumab, to treat patients with multiple myeloma who have failed previous therapies. By utilizing a bispecific antibody alongside a monoclonal antibody, this dual approach aims to bridge immune cells directly to cancer cells for more efficient destruction. The research demonstrates that this novel combination significantly improves progression-free survival and achieves higher rates of complete remission compared to standard treatment regimens. While the combination therapy offers a…